A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
Status: Recruiting
Location: See all (9) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Subjects have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
• Male or female subjects ≥ 18 years old;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
• Anticipated life expectancy of ≥ 3 months;
Locations
United States
California
University of California, San Francisco (UCSF)
RECRUITING
San Francisco
Florida
Ocala Oncology Center
RECRUITING
Ocala
BRCR Medical Center
RECRUITING
Plantation
Kansas
University of Kansas Medical Center (KUMC)
RECRUITING
Fairway
Michigan
Michigan Hematology & Oncology Consultants - MedOnc Dearborn
RECRUITING
Dearborn
Michigan Hematology & Oncology Consultants - MedOnc Troy
RECRUITING
Troy
Texas
MD Anderson Cancer Center-University of Texas
RECRUITING
Houston
Oncology Consultants P.A.
RECRUITING
Houston
Washington
Fred Hutchinson Cancer Center
RECRUITING
Seattle
Contact Information
Primary
Amanda Guo
amanda.guo@innoventbio.com
1-832-207-5244
Backup
William Liu
william.liu01@innoventbio.com
1-917-436-6817
Time Frame
Start Date: 2024-04-08
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 178
Treatments
Experimental: IBI363
IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks.
Related Therapeutic Areas
Sponsors
Leads: Innovent Biologics (Suzhou) Co. Ltd.